Target intelligence / Profile preview

Vacuolar-type proton ATPase (osteoclast-specific isoform containing the a3 subunit) (V-ATPase (a3 subunit))

Target
V-ATPase (a3 subunit)
Molecular classification
Enzyme, ATPase, Proton pump, Vacuolar H+-ATPase family
01

Overview

Vacuolar-type proton ATPase (V-ATPase) is a multisubunit ATP-dependent enzyme complex located in the ruffled border of osteoclasts, where it acidifies the extracellular resorption compartment by pumping protons against a large gradient, using the energy from ATP hydrolysis[3][4]. This acidification is essential for the demineralization of bone and activation of proteolytic enzymes needed to degrade the organic bone matrix[2][4][6]. The osteoclast-specific isoform includes the a3 subunit (encoded by TCIRG1), which is required for normal bone turnover, and mutations cause osteopetrosis, a disease characterized by defective bone resorption[3][6]. V-ATPase is a validated therapeutic target for bone diseases such as osteoporosis, although clinical development of inhibitors is limited by safety concerns due to the enzyme’s presence in multiple tissues[3][4].

Other names
Osteoclastic V-ATPaseVacuolar H+-ATPase (a3)TCIRG1 (gene encoding a3 subunit)Osteoclast proton pump
02

Mechanism of action

Inhibition of ATP hydrolysis blocks proton transport, acidification, and bone matrix dissolution[3][4]. Inhibition prevents formation of acidic environment necessary for proteolytic enzymes (e.g., cathepsin K) to degrade bone[4].

03

Biological functions

Bone resorptionAcidification of resorptive lacunaLysosomal functionCellular energy metabolism (ATP hydrolysis)
04

Disease associations

OsteoporosisOsteopetrosis (loss-of-function or mutations)Other bone remodeling disorders
05

Safety considerations

V-ATPase is present in other tissues, so inhibition risk of off-target toxicity (e.g., kidney, brain, general lysosomal function)[3]General issues with targeting basic cellular energy metabolism (cell viability)
06

Interacting drugs

Bafilomycin A1 (experimental inhibitor; not used clinically)

2 more in the full profile.

07

Biomarkers

Mutations in TCIRG1 (a3 subunit) for osteopetrosis diagnosis[3]Bone resorption markers (e.g., CTX, NTX) for efficacy monitoring

Beyond the preview

Go deeper on Vacuolar-type proton ATPase (osteoclast-specific isoform containing the a3 subunit) (V-ATPase (a3 subunit)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vacuolar-type proton ATPase (osteoclast-specific isoform containing the a3 subunit) (V-ATPase (a3 subunit)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call